PITTSBURGH, Sept. 2, 2025 /PRNewswire/ — Green Cabbage, the global leader in procurement intelligence, proudly announces the appointment of Michael Van Keulen (MVK) as its new Chief Client Officer (CCO). With more than 15 years of experience in procurement and supply chain leadership across high-growth retail companies and, most recently, as Chief Procurement Officer and Practice Leader at Coupa, MVK brings an unmatched blend of strategic insight, operational excellence, and global perspective to the Green Cabbage executive team.

Born in Amsterdam, MVK is truly a citizen of the world, having lived in five countries: the Netherlands, Belgium, USA, Canada, and now Portugal. Together with his wife and three children, whose diverse birthplaces span Belgium and Canada, his family proudly embodies what he calls “a true United Nations.” Outside of work, he is a passionate sports fan, with loyalty to European football, Major League Baseball’s New York Yankees, and Formula 1 racing.

“As a practitioner, I have always believed in making fact-based decisions, doing my homework, and establishing strong relationships with internal and external stakeholders,” said MVK. “In the age of AI having reliable, structured, governed and trusted data is critical to understanding the competitive landscape, where there is leverage, while optimizing the value of spend requires the right intelligence at your fingertips. That is exactly what Green Cabbage has created, and this is the perfect time to help scale and grow globally across all verticals. I am truly inspired by the measurable value Eric, and the team are delivering to the procurement community, and excited about the journey ahead.”

MVK began his career in Finance before transitioning into Procurement and Supply Chain, where he built a reputation for leading transformation, driving measurable savings, and implementing innovative sourcing strategies. His appointment signals a major step in Green Cabbage’s continued growth following its recent Series A funding and its mission to transform how companies manage Indirect Technology, Contingent Workforce, Marketing, and Travel & Expense spend.

Eric Cunningham, CEO and Founder of Green Cabbage, shared his excitement about the new CCO:

“We are thrilled to welcome MVK to Green Cabbage. His experience as both a practitioner and global leader, combined with his passion for innovation, aligns perfectly with our mission to deliver unmatched procurement intelligence and client value. His leadership will be critical as we continue to scale globally and bring the best solutions to our clients at a pace the market has never seen before.”

Green Cabbage’s appointment of MVK as CCO represents a pivotal moment in its journey to redefine procurement intelligence worldwide, reinforcing its commitment to empowering organizations with the insights, tools, and negotiation strategies needed to drive 15–30% savings and sustainable business growth. Hiring him will help us drastically upskill our people and scale the most horizontally diverse platform the market has ever seen.

About Green Cabbage:
Green Cabbage is a global leader in procurement and workforce market intelligence, helping organizations optimize spend across indirect technology, contingent workforce, marketing, and travel & expense categories. Through its proprietary OneWorkspace platform and executive relationships, Green Cabbage delivers measurable value, enabling companies to achieve 15–30% savings with a guaranteed minimum 5X ROI.

For more information, visit: www.greencabbage.com

Media Contact: Alex Fochler, alex.fochler@green-cabbage.com

PANAMA CITY, Sept. 2, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, today announced the conclusion of its meaningful initiative at the Long Đất Nursing Center for War Invalids and People with Meritorious Services in Bà Rịa–Vũng Tàu. As the only facility of its kind in Southern Vietnam dedicated to severely wounded veterans, this Center is of profound importance to the country.

During the visit, the BingX team, alongside representatives from community partners, donated over 70 million VND in support, including 50 care packages, 15 million VND in direct contributions, and essential household appliances such as clothes dryers, refrigerators, and cooking utensils, and an additional 5 million VND was contributed directly to a Vietnamese Heroic Mother. The day included warm exchanges with veterans, cultural performances, health check-ins, and visits to residents, underscoring BingX’s dedication to providing both material and emotional support.

Vivien Lin, Spokesperson at BingX, commented: “To BingX, our initiative at Bà Rịa–Vũng Tàu represents the responsibility and obligation we have to the community as an organization. Through our work here, we aim to build human connections, show respect, and reinforce our commitment to community care. As we continue to innovate in finance and technology, we also strive to ensure our growth creates a positive impact on the world we live in.”

This effort builds on BingX’s track record of charitable initiatives in Vietnam and worldwide. In 2024, BingX donated 400 million VND to support recovery efforts following Typhoon Yagi, later matching public donations to bring the total contribution to 1 billion VND. The company also co-sponsored the upgrade of vital road and bridge infrastructure in Ben Tre Province, improving transportation and quality of life for local residents. Beyond Vietnam, BingX has partnered with international organizations such as Whale and Dolphin Conservation (WDC) to advance global sustainability and wildlife protection.

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information please visit: https://bingx.com/

MELBOURNE, Australia, Sept. 2, 2025 /PRNewswire/ — Firstsource Solutions Limited (NSE: FSL) (BSE: 532809), a leading global provider of specialist domain-led Business Process Services (BPS) and an RP-Sanjiv Goenka Group company, has been recognized as a Horizon 3 Market Leader in HFS Research’s HFS Horizons: The Best Service Providers for Mortgage Reinvention, 2025 report. The Horizon 3 positioning – the highest category in the HFS Horizons framework, recognizes Firstsource’s ability to deliver end-to-end mortgage modernization through full ecosystem collaboration, technology innovation, and transformation-led partnerships. Powered by a tech-enabled, operations-first approach and its subsidiary, Sourcepoint, the company delivers a multi-touchpoint borrower experience across the mortgage lifecycle, from origination and underwriting to closing, servicing, defaults, and product upgrades.

Firstsource named Horizon 3 Market Leader in HFS Horizons: The Best Service Providers for Mortgage Reinvention, 2025

HFS Research evaluated global service providers on their vision, execution, and market impact across the mortgage value chain. Firstsource earned its Horizon 3 Market Leader recognition for reimagining the borrower experience from application to loan disposition, investing in mortgage-specific GenAI innovation, and deploying its differentiated UnBPO™ model to deliver measurable client outcomes. 

Vivek Sharma, Head – BFS, CMT, and Emerging Geos, Firstsource, shared, “Being named a Horizon 3 Market Leader by HFS validates the bold reinvention journey we’ve undertaken in mortgages. We are moving the industry away from labor-heavy models toward transformation-first operations, powered by deep domain expertise and ecosystem partnerships. What truly sets us apart is our work on building custom, industry-specific mortgage language model – not just applying generic AI, but engineering GenAI that understands the mortgage lifecycle end to end. This innovation is enabling faster decisions, seamless borrower experiences, and greater resilience for lenders – reiterating the power of our UnBPOᵀᴹ mindset in modernizing the mortgage value chain end to end and shaping the future of lending.”

Divya Iyer, Practice Director, BFSI, HFS Research, shared, “The mortgage industry is battling to build resilience and protect margins in a compliance-heavy landscape, navigating interest rate volatility, inflation, and housing market swings. The old playbook of flexing operations through sheer people is dead. The year 2025 marks an inflection point—growth, cost, and profitability now hinge on technology and innovation-led operations, not headcount. Service providers will be pivotal in driving this shift toward modernization and innovation, keeping lenders competitive once they get there.”

Key highlights from the report:

• Owning the borrower experience: Reimagining the mortgage journey end to end, from origination to post-close, defaults, and product upgrades, supported by Sourcepoint, a Firstsource company, and a tech-enabled, operations-first approach.
• Mortgage-specific GenAI leadership: Proprietary Mortgage LLM trained on industry data for contextual intelligence, with relAI enabling responsible, plug-and-play GenAI deployment across origination and servicing.
• Integrated suite for smaller lenders: API-integrated proprietary assets covering the mortgage value chain to accelerate digitization and interoperability.
• UnBPO™: a transformative shift away from traditional outsourcing. By prioritizing expertise, innovation, and outcome-driven solutions, Firstsource is redefining the industry and building a future-ready organization.
• Robust global delivery footprint: 8 delivery centers worldwide, including an AI CoE for mortgage, serving 500+ clients – 2 of the top 5 US banks and, 12 of the top 20 mortgage lenders/servicers – as well as providing support for nearly 20% of the UK mortgage market.

To download a copy of the report, please visit: https://www.firstsource.com/about/analyst-recognitions/firstsource-hfs-mortgage-award-2025

About Firstsource

Firstsource Solutions Limited, an RP-Sanjiv Goenka Group company (NSE: FSL) (BSE: 532809) (Reuters: FISO.BO) (Bloomberg: FSOL:IN), is a global leader providing business process solutions and services spanning the customer lifecycle across Healthcare, Banking and Financial Services, Communications, Media and Technology, Retail, and other diverse industries. With a global footprint across US, UK, India, Philippines, Mexico, Romania, Turkey, Trinidad & Tobago, South Africa, and Australia, we ‘make it happen’ for our clients, solving their biggest challenges with hyper-focused, domain-centered teams and cutting-edge tech, data, and analytics. Our inch-wide, mile-deep practitioners work collaboratively, leveraging UnBPO™ – our differentiated approach to reimagining traditional outsourcing – to deliver real-world, future-focused solutions that drive speed, scale, and smarter decision, turning transformation into tangible results for our clients. (www.firstsource.com)

About HFS Research
HFS Research is a leading research and advisory authority on enterprise transformation, serving Fortune 500 companies with fearless insights and actionable strategies. With unparalleled access to Global 2000 executives and deep expertise in AI, automation, and digital business models, HFS empowers organizations to make confident decisions that create sustainable competitive advantage. For more information, visit hfsresearch.com.

NEW YORK, Sept. 2, 2025 /PRNewswire/ — Gemini Space Station, Inc. (“Gemini”), a global crypto platform, today announced the launch of its initial public offering of 16,666,667 shares of Class A common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “SEC”). In connection with the offering, Gemini and the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 2,396,348 and 103,652 shares of Class A common stock, respectively, to cover over-allotments. The initial public offering price is currently expected to be between $17.00 and $19.00 per share of Class A common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Gemini has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “GEMI.”

Goldman Sachs & Co. LLC and Citigroup are acting as lead bookrunners. Morgan Stanley and Cantor are also acting as lead bookrunners. Evercore ISI, Mizuho, Truist Securities, Cohen & Company Capital Markets, Keefe, Bruyette & Woods, A Stifel Company, Needham & Company, and Rosenblatt are acting as bookrunners. Academy Securities, AmeriVet Securities, and Roberts & Ryan are acting as co-managers.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or email: prospectus-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gemini

Gemini is a global crypto platform founded by Cameron and Tyler Winklevoss in 2014. Gemini offers a wide range of crypto products and services for individuals and institutions in over 60 countries. Gemini’s simple, reliable, and secure products are built to unlock the next era of financial, creative, and personal freedom.

Contact

Natalie Rix
Email: press@gemini.com 

NEW YORK, Sept. 2, 2025 /PRNewswire/ — Integrated Sensing and Communications (ISAC) is a key concept being developed for 6G, which transforms cellular networks into radars and allows them to both sense their environment and communicate information about it. Although there are significant technical challenges to bring this to market, it is a concept that can revolutionize mobile networks and allow Mobile Network Operators (MNOs) to finally become much more than a data pipe, according to ABI Research, a global technology intelligence firm. The commercial opportunities for ISAC are substantial and offer MNOs a chance to get into new markets, parts of which are not served by other technologies or companies.

“ISAC is a unique opportunity for mobile operators to break free of their connectivity legacy,” said Dimitris Mavrakis, Senior Research Director at ABI Research. “Coupled with network APIs, they can become brokers for location and positioning across their network footprint, helping enterprises locate their assets and protect their locations. Mobile operators cannot afford to ignore ISAC, as it is key for them to continue growing their business. It is the first truly innovative concept discussed for cellular networks since 4G introduced mobile broadband.”

In 2025, vendors and mobile operators are conducting live commercial trials to understand the technical and commercial implications of deploying ISAC, while ETSI, 3GPP, and other industry bodies are continuing their standardization efforts. Initial trials in China indicate that there is some commercial interest in sensing, mostly driven by the low-altitude economy, but it is still too early to understand if the new technology makes commercial sense. The challenge is compounded by the fact that a fully capable ISAC radio is not backward compatible with existing 5G infrastructure, meaning that an upgrade could cost upwards of $50,000 to $100,000 per cell site. This may not be something mobile operators are willing to risk at the current stage of the market, but demand and economies of scale will bring prices down while exposing the market to ISAC’s capabilities.

ISAC is a unique and challenging opportunity, and vendors are currently investing in R&D and filing for relevant patents. Although it’s early, ISAC has the capability to completely redefine the market and upset the long-established dynamics while creating burgeoning new ecosystem. As such, early adopters are starting to assess the technology today, when the interest, hype, and investment around ISAC is just ramping up.

These findings are from ABI Research’s Integrated Sensing and Communications: Market Developments & Use Case Analysis report, part of the company’s 5G, 6G, and Open RAN research service, which includes research, data, and ABI Insights. 

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info: 

Global
Jason Scheer
Tel: +1.516.624.2558
pr@abiresearch.com 

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 – 15 in Copenhagen, Denmark:

• EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS^® PathFinder^™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients.
• NEW STANDARDS IN SURGICAL EXCELLENCE: showcasing the DORC EVA NEXUS^™ dual strategy surgical platform as part of ZEISS’s expanding surgical workflow solutions.
• IMPROVED PREDICTABILITY OUTCOMES: updated ZEISS VISULYZE 1.2 data analysis and personalized nomogram creation software tool now with ZEISS FORUM integration for more convenient and efficient nomogram creation within the ZEISS Corneal Refractive Workflow.
• REFRACTIVE INDUSTRY MILESTONES: more than 12 million eyes treated with ZEISS SMILE and ZEISS SMILE pro; also celebrating ongoing market traction of SMILE^® pro for treating hyperopia.
• CATARACT MILESTONES: celebrating more than 10 million cataract surgeries using VisionBlue^® anterior stain from DORC, a ZEISS company; celebrating key IOL milestones validated by multiple clinical studies presented at ESCRS.

JENA, Germany, Sept. 2, 2025 /PRNewswire/ — ZEISS Medical Technology showcases the latest innovations and enhancements to its cataract and corneal refractive workflow solutions, from diagnostics and surgical planning to advanced treatments, at the European Society of Cataract and Refractive Surgeons (ESCRS) conference in Copenhagen, Denmark, from Sept. 12-15, 2025.

ZEISS VISULYZE 1.2 software

“ZEISS continues to introduce advanced optical and digital innovation to meet the expanding needs of Europe’s leading refractive and cataract surgeons,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “From major industry milestones to new digital workflow solutions, our industry leadership shines bright, setting new standards for ophthalmic care.”

Advancements deliver improved efficiencies in surgical planning

From advanced imaging to cloud-enabled data access, ZEISS diagnostic and digital solutions integrated into ophthalmic workflows can help surgeons visualize more, connect insights across a workflow, and make data-driven decisions, including earlier detection of eye conditions that may affect surgical planning and outcomes. At ESCRS, ZEISS will demonstrate a fully integrated solution connecting cataract and glaucoma workflows to support more efficient and confident decision making.

Glaucoma is the most common comorbidity in cataract surgery. According to a recent study¹, around 20% of patients who undergo cataract procedures also have glaucoma or ocular hypertension. ZEISS offers integrated diagnostic and therapeutic solutions to support earlier detection and management of glaucoma in cataract patients, helping to improve long-term outcomes of cataract surgery. Devices including the ZEISS SL 800, CLARUS^®, CIRRUS^® OCT, ARTEVO^® 750, and VISULAS^® combi (yag/slt) are shared across the cataract and glaucoma workflows and seamlessly connected via FORUM^® for complete data continuity.

“It’s an exciting time to be an ophthalmologist. I’m extremely grateful to companies like ZEISS Medical Technology, that bring us products which are truly game changers in the care of our glaucoma and cataract patients,” said Dr. Steven Vold, Founder and Chief Executive Officer of Vold Vision (Florida, USA).

ZEISS will also showcase CIRRUS^® PathFinder™, which recently received CE mark approval, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician’s patient care workflow with OCT interpretation assistance, supporting improved surgical planning, particularly for high-volume clinics. The AI-powered OCT assessment tool is fully integrated into ZEISS CIRRUS², using proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed capability of the latest CIRRUS software release, helping to improve a practice’s efficiency and patient care outcomes.

At ESCRS, the company will celebrate ZEISS CIRRUS PathFinder as a major step forward in AI and diagnostics, unveiling the progress made to date with the latest innovation in CIRRUS OCT technology including a presentation by Dr. Leo Seo Wei, MD, sharing her first impressions and expertise on Sunday, Sept. 14, at 3:00 PM CET in the ZEISS booth #C1.130.  

Leading the way in refractive surgery with SMILE^® pro for hyperopia and advanced digitally connected patient planning

The ZEISS Corneal Refractive Workflow empowers surgeons to optimize patient flow while growing their practice with added value beyond the devices through targeted services that help improve patient outcomes through a digitally connected and streamlined clinical workflow. At ESCRS, ZEISS will showcase a new version of its comprehensive data analysis and personalized nomogram creation software tool, ZEISS VISULYZE 1.2, now connected to ZEISS FORUM so refractive surgeons can access their imported data with one click, offering convenience and efficiency during the nomogram creation process. The software update provides transparency into factors that can affect patient outcomes, allowing those insights to be transferred to the refractive laser as well as to the next treatment plan, reducing manual work and risks of transcription errors. With ZEISS FORUM integration, the ZEISS VISULYZE 1.2 software helps improve predictability and outcomes to support higher patient satisfaction.

ZEISS continues to extend its global refractive industry momentum with the celebration of more than 12 million eyes treated with ZEISS SMILE and ZEISS SMILE pro, reflecting the growing international adoption of the technology for a minimal invasive lenticule extraction procedure. The company is also celebrating one year of SMILE^® pro for treating hyperopia, now available in 56 countries. ZEISS is the only provider offering a treatment for hyperopia with lenticule extraction, representing a promising advancement in refractive surgery with outcomes comparable to hyperopic LASIK. ZEISS SMILE and ZEISS SMILE pro continue to be leading solutions trusted by surgeons for the technology’s proven reliability and effective treatment with the VisuMax^® and VISUMAX^® 800 from ZEISS.

ESCRS attendees can learn more about the latest refractive offerings within the ZEISS Corneal Refractive Workflow at the ZEISS booth #C1.130, including a presentation on Sunday, Sept. 14, at 10:00 AM CET from Prof. Dr. Dan Reinstein, London Vision Clinic (UK), who will share his expert insights and valuable firsthand experience with ZEISS SMILE pro for hyperopia.

Celebrating industry milestones and unparalleled optics within an integrated cataract workflow

Setting new standards in surgical excellence, ZEISS is delivering industry-leading efficiency through digitally integrated solutions and unparalleled optics. At ESCRS, the ZEISS Cataract Workflow will include a robust portfolio of surgical solutions, including the 3D heads-up technology of the ZEISS ARTEVO 850, optical visualization with a novel light source with the ZEISS ARTEVO 750, the ZEISS EQ Workplace and ZEISS Surgery Planner digital cataract planning solutions, and the patented ZEISS QUATTRO pump of the QUATERA^® 700 from ZEISS to experience chamber stability independent of IOP and flow. ZEISS will also showcase next to its primary cataract workflow the DORC EVA NEXUS™ platform, uniquely suited to address both retina and cataract surgery, now with availability of angled EquiPhaco designed for optimal irrigation flow. EquiPhaco, combined with EVA NEXUS SMART IOP™, allows for a more stable, lower anterior chamber pressure during procedures.

ZEISS is also celebrating key product milestones, including a special event with Dr. Elena Barraquer in the ZEISS booth #C1.130 on Saturday, Sept. 13, at 3:00 PM CET to highlight more than 10 million cataract surgeries conducted using VisionBlue^® anterior stain from DORC, reflecting the solution’s continued leadership in the market as the only trypan blue stain for anterior use approved by the FDA and now approved for staining of Descemet’s membrane and trabecular meshwork.

Additionally, ZEISS is celebrating IOL clinical milestones which reflect the company’s expertise in optics, featuring two distinct high-quality biomaterials and lens designs. Dr. Andrea Janeková from Eye Center Prague in Czech Republic says, “As the first peer-reviewed study on the AT ELANA^® 841P, the data confirm that it delivers excellent distance, intermediate, and near vision with minimal photic phenomena, meeting the expectations of both surgeons and patients. What stood out most to me was the smooth and extended defocus profile of the AT ELANA 841P, which translated into functional vision across a wide range and high patient satisfaction.” Dr. Mfazo Hove from Blue Fin Vision in the UK says, “I knew the AT LISA^® tri lenses were good – my patients repeatedly told me. They have exceeded all my expectations since having them implanted 18 months ago. I might even have become a better surgeon – the numbers don’t lie. PC rupture 0.2% off 5,600 operations in 12 months down from 0.27%.”

As part of an IOL clinical milestone celebration in the ZEISS booth #C1.130 on Saturday, Sept. 13, at 10:00 AM CET, the ZEISS IOL portfolio will be validated through multiple clinical studies and direct ZEISS IOL experience presented by industry experts including Prof. Gerd U. Auffarth (Heidelberg, Germany) and Dr. Kyungmin Koh (Seoul, Republic of Korea), as well as Dr. Andrea Janeková and Dr. Mfazo Hove.

ZEISS will showcase its latest offerings and new innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference from Sept. 12 – 15, 2025, at booth #C1.130.

For more information, visit www.zeiss.com/med.  

¹ Skalicky, S.E., Martin, K.R., Fenwick, E., Crowston, J.G., Goldberg, I. and McCluskey, P. (2015), Cataract and quality of life in glaucoma. Clin Experiment Ophthalmol, 43: 335-341. https://doi.org/10.1111/ceo.12454.
² ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

Contact for investors
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.med@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

www.zeiss.com/newsroom

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med 

CIRRUS® PathFinder™ AI-powered OCT assessment tool

DORC EVA NEXUS™

Celebrating more than 12 million eyes treated with SMILE® and SMILE® pro from ZEISS.

Celebrating more than 10 million cataract surgeries conducted using VisionBlue® anterior stain from DORC.